Skip to main content
Premium Trial:

Request an Annual Quote

DNA Sciences, Bristol-Myers Enter Drug-Discovery Deal

NEW YORK, Oct. 9 – Beleaguered functional genomic firm DNA Sciences intends to partner with Bristol-Myers Squibb to investigate genetic variants within an undisclosed drug-discovery gene target, the companies said on Tuesday.

Terms of the deal call for DNA Sciences to use its high-throughput sequencing and genotyping facility to study Bristol-Myers’ gene in normal and affected disease populations.

Both companies plan to use any findings from the collaboration in future research and development activities, according to a statement.

Financial terms were not disclosed.

As GenomeWeb reported , Fremont, Calif.-based DNA Sciences last month sacked its chairman and CEO, Hugh Reinhoff, and announced plans to lay off roughly half of its workforce.

The change at the top reflects the company’s intent to change from a traditional genomic platform to one that develops and commercializes diagnostic and drug-discovery products.

In the statement released on Tuesday, Steven Lehrer, DNA Sciences’ new president and COO, said: “Our effort with Bristol-Myers Squibb is a continuation of DNA Sciences' goal to apply genetics to pharmaceutical discovery and development.”

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.